# Study on the Performance and Safety of Sentinox in COVID-19 Patients

> **NCT04909996** · NA · COMPLETED · sponsor: **APR Applied Pharma Research s.a.** · enrollment: 57 (actual)

## Conditions studied

- COVID-19 (SARS-CoV-2 Infection)

## Interventions

- **DEVICE:** Sentinox--Group A
- **DEVICE:** Sentinox--Group B

## Key facts

- **NCT ID:** NCT04909996
- **Lead sponsor:** APR Applied Pharma Research s.a.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909996, "Study on the Performance and Safety of Sentinox in COVID-19 Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04909996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*